Detalhe da pesquisa
1.
Effectiveness of antibacterial therapeutic clothing vs. nonantibacterial therapeutic clothing in patients with moderate-to-severe atopic dermatitis: a randomized controlled observer-blind pragmatic trial (ABC trial).
Br J Dermatol
; 190(3): 342-354, 2024 Feb 16.
Artigo
Inglês
| MEDLINE | ID: mdl-37936331
2.
Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: up to 5-year results from the daily practice BioDay Registry.
J Am Acad Dermatol
; 2024 Apr 21.
Artigo
Inglês
| MEDLINE | ID: mdl-38653344
3.
Real-world Experience of Abrocitinib Treatment in Patients with Atopic Dermatitis and Hand Eczema: Up to 28-week Results from the BioDay Registry.
Acta Derm Venereol
; 104: adv19454, 2024 02 07.
Artigo
Inglês
| MEDLINE | ID: mdl-38323500
4.
Successful tapering of dupilumab in patients with atopic dermatitis with low disease activity: a large pragmatic daily practice study from the BioDay registry.
Br J Dermatol
; 189(3): 327-335, 2023 08 24.
Artigo
Inglês
| MEDLINE | ID: mdl-37177895
5.
Effectiveness of Upadacitinib in Patients with Atopic Dermatitis including those with Inadequate Response to Dupilumab and/or Baricitinib: Results from the BioDay Registry.
Acta Derm Venereol
; 103: adv00872, 2023 Feb 16.
Artigo
Inglês
| MEDLINE | ID: mdl-36794894
6.
Patient-centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis.
Allergy
; 77(11): 3398-3407, 2022 11.
Artigo
Inglês
| MEDLINE | ID: mdl-35837880
7.
Dupilumab in daily practice for the treatment of pediatric atopic dermatitis: 28-week clinical and biomarker results from the BioDay registry.
Pediatr Allergy Immunol
; 33(12): e13887, 2022 12.
Artigo
Inglês
| MEDLINE | ID: mdl-36564878
8.
Daily Practice Experience of Baricitinib Treatment for Patients with Difficult-to-Treat Atopic Dermatitis: Results from the BioDay Registry.
Acta Derm Venereol
; 102: adv00820, 2022 Nov 24.
Artigo
Inglês
| MEDLINE | ID: mdl-36420885
9.
Differential dynamics of TARC during JAK-inhibitor therapy compared to biological therapies targeting type 2 inflammation.
Clin Exp Allergy
; 54(4): 294-296, 2024 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-38158774
10.
Muscle and joint pain during dupilumab treatment for atopic dermatitis: Lack of association with antinuclear antibodies.
Clin Exp Allergy
; 53(5): 582-585, 2023 05.
Artigo
Inglês
| MEDLINE | ID: mdl-36779570
11.
Ocular surface disease is common in moderate-to-severe atopic dermatitis patients.
Clin Exp Allergy
; 52(6): 801-805, 2022 06.
Artigo
Inglês
| MEDLINE | ID: mdl-35294787
12.
Dupilumab-Associated Lymphoid Reactions in Patients With Atopic Dermatitis.
JAMA Dermatol
; 159(11): 1240-1247, 2023 11 01.
Artigo
Inglês
| MEDLINE | ID: mdl-37851456
13.
Association of Serum Dupilumab Levels at 16 Weeks With Treatment Response and Adverse Effects in Patients With Atopic Dermatitis: A Prospective Clinical Cohort Study From the BioDay Registry.
JAMA Dermatol
; 158(12): 1409-1413, 2022 12 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36322072
14.
Eczema control and treatment satisfaction in atopic dermatitis patients treated with dupilumab - a cross-sectional study from the BioDay registry.
J Dermatolog Treat
; 33(4): 1986-1989, 2022 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-34151695
15.
Dupilumab Drug Survival and Associated Predictors in Patients With Moderate to Severe Atopic Dermatitis: Long-term Results From the Daily Practice BioDay Registry.
JAMA Dermatol
; 158(9): 1048-1056, 2022 09 01.
Artigo
Inglês
| MEDLINE | ID: mdl-35947364